The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence

Bibliography

• WHO.WHO/UNODC/UNAIDS position paper: substitution maintenance therapy in the management of opioid dependence and HIV/AIDs prevention. Geneva: World Health Organisation; 2004
   Google Scholar
• Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000;22(3):179-90
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002207
   Google Scholar
• WHO. WHO Essential medicines library. Geneva: WHO; 2005
   Google Scholar
• Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction 2001;96(2):267-72
   PubMed Web of Science ®Google Scholar
• Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69(2):175-81
   PubMed Web of Science ®Google Scholar
• Fountain J, Strang J, Gossop M, et al. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000;95(3):393-406
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996;43(3):191-8
   PubMed Web of Science ®Google Scholar
• Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev 2002;21(1):27-32
   PubMed Web of Science ®Google Scholar
• Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33(1):81-6
   PubMed Web of Science ®Google Scholar
• Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100(2):197-205
   PubMed Web of Science ®Google Scholar
• Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002;21(2):131-6
   PubMed Web of Science ®Google Scholar
• Larance B, Degenhardt L, Mattick R, et al. The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone, 2006-2008. NDARC Technical Report. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2009
   Google Scholar
• Guichard A, Lert F, Calderon C, et al. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003;98(11):1585-97
   PubMed Web of Science ®Google Scholar
• Neeleman J, Farrell M. Fatal methadone and heroin overdoses; time trends in England and Wales. J Epidemiol Community Health 1997;51:435-7
   PubMed Web of Science ®Google Scholar
• Parfitt T. Designer drug Subutex takes its toll in Tbilisi. Lancet 2006;368:273-4
   PubMed Web of Science ®Google Scholar
• Sunjic S, Zador D. Methadone-related deaths in New South Wales. Med J Austr 1997;166(1):54-5
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285(1):45
   PubMed Web of Science ®Google Scholar
• Bell J, Butler B, Lawrance A, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009;104(1-2):73-7
   PubMed Web of Science ®Google Scholar
• Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003;70(2 Suppl 1):S3-11
   PubMed Web of Science ®Google Scholar
• Gowing L, Ali R, White J, et al. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006;(2):CD002025
   PubMedGoogle Scholar
• Ferri M, Davoli M, Perucci C. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2005;(2):CD003410
   PubMedGoogle Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006;(1):CD001333
   PubMedGoogle Scholar
• Lobmaier P, Kornor H, Kunoe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD006140
   PubMed Web of Science ®Google Scholar
• Orman JS, Keating GM. Buprenorphine/Naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009;69(5):577-607
   PubMed Web of Science ®Google Scholar
• Bell J, Shearer J, Ryan A, et al. The acceptability, safety and tolerability of methadone/naloxone in a 50:1 ratio. Exp Clin Psychopharmacol 2009;17(3):146-53
   PubMed Web of Science ®Google Scholar
• Sobel B, Sigmon S, Walsh S, et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2003;73(1):11-22
   Web of Science ®Google Scholar
• Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 2003;70(2 Suppl 1):S29-37
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35(4):501-16
   PubMed Web of Science ®Google Scholar
• Marquet P. Pharmacology of high dose buprenorphine. In: Kintz P, Kintz P, Marquet P, editors, Buprenorphine Therapy of Opiate Addiction. Totowa, New Jersey: Humana Press; 2002. p. 1-11
   Google Scholar
• Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44(7):661-80
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(2 Suppl 1):S39-47
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984;12(5):577-81
   PubMed Web of Science ®Google Scholar
• Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000;61(1):85-94
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55(5):569-80
   PubMed Web of Science ®Google Scholar
• White JM, Lopatko OV. Opioid maintenance: a comparative review of pharmacological strategies. Expert Opin Pharmacother 2007;8(1):1-11
   PubMed Web of Science ®Google Scholar
• Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology 2002;159(2):161-6
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 1988;94(4):484-90
   PubMed Web of Science ®Google Scholar
• Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 1997;41(11):1095-101
   PubMed Web of Science ®Google Scholar
• Mendelson J, Jones RT, Fernandez I, et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 1996;60(1):105-14
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Yu E, Macfadden W, et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998;50(1):1-8
   PubMed Web of Science ®Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001;154(3):230-42
   PubMed Web of Science ®Google Scholar
• Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002;303(2):695-703
   PubMed Web of Science ®Google Scholar
• Weinhold LL, Preston KL, Farre M, et al. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992;30(3):263-74
   PubMed Web of Science ®Google Scholar
• Strain EC, Stoller K, Walsh SL, Bigelow GE. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 2000;148(4):374-83
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58
   PubMed Web of Science ®Google Scholar
• Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 2008;10(4):5-18
   Google Scholar
• Johnson RE, Eissenberg T, Stitzer ML, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995;40:17-25
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. One year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden; a randomised, placebo-controlled trial. Lancet 2003;361:662-8
   PubMed Web of Science ®Google Scholar
• Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007;102(12):1899-907
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355(4):365-74
   PubMed Web of Science ®Google Scholar
• Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of Buprenorphine in the United States – 2003-2005. J Addict Dis 2007;26(3):107-11
   PubMed Web of Science ®Google Scholar
• Bruce RD, Govindasamy S, Sylla L, et al. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009;35(2):68-72
   PubMed Web of Science ®Google Scholar
• Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88(1):75-8
   PubMed Web of Science ®Google Scholar
• Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous Buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 2004;24(5):479-87
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003;98(4):441-52
   PubMed Web of Science ®Google Scholar